Tag Archives: cancer

Metro Areas Where Employers Influence Cancer Coverage Costs

Metro Areas Where Employers Influence Cancer Coverage Costs. Employers currently represent approximately 60% of the commercial insurance market dollars. The Employer commercial insurance market consists of more than 95,000 companies with self-insured plans, eighty percent of whom have less than 2,000 employees. Entering 2017, these employers face double-digit increases in the cost of prescription drugs […]

Designing Pharmacy and Medical Benefits for Cancer Care

Designing Pharmacy and Medical Benefits for Cancer Care: An Employer Perspective – published in Value-Based Cancer Care F. Randy Vogenberg, PhD, RPh, FASHP; Catherine E. Cooke, PharmD, BCPS October 2016, Vol 7, No 9 – Employers’ Perspective With the increasing complexity of cancer care after the passing of the 2010 Affordable Care Act, employers as […]

Telehealth Applications Patient Care

Telehealth Applications Patient Care Rita M. Marcoux, RPh, MBA; F. Randy Vogenberg, PhD, RPh, FASHP June 2016, Vol 7, No 5 – Employers’ Perspective – Value-Based Cancer Care The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using […]

Oncology Biosimilars: Opportunity or Not?

Oncology Biosimilars: Opportunity or Not? VBCC – April 2016, Vol 7, No 3 – Employers’ Perspective F. Randy Vogenberg, PhD, RPh, Partner Access Market Intelligence Martha M. Rumore, PharmD, JD, MS, LLM, FAPhA The United States has the largest biologic drugs market and high prices for biologics, such as monoclonal antibodies, therapeutic proteins, immunomodulators, and […]

Big Data in Cancer Care: Limitations of Drug Claims

Big Data in Cancer Care: Limitations of Drug Claims VBCC – March 2016, Vol 7, No 2 – Employers’ Perspective Catherine E. Cooke, PharmD, BCPS F. Randy Vogenberg, PhD, RPh Partner, National Institute of Collaborative Healthcare, and Access Market Intelligence; Principal, Institute for Integrated Healthcare Greenville, SC As one part of an ongoing macrotheme regarding big […]

Impact of Commercial Insurance in 2017

Clinical trial collaborations – an idea whose time has come

Impact of Commercial Insurance in 2017 – Considerable attention and planning has been focused on the Medicare market, but as we see from the chart below, Medicare represents approximately 13% of the total population.   Employer 49% Medicaid 19% Medicare 13% Uninsured 10% Non-Group 6% Other Public 2% (Source: Kaiser Family Foundation) A recent Mercer […]

Oncology Care Marketing Increasing

Knowsource.com Announces Transition to Access Market Intelligence

Oncology care marketing increasing in the U.S. marketplace. However, continuing benefit coverage planning for 2017 are also topics that are receiving increasing attention—to include cancer care. Just as the new oncology product pipeline is providing new options or treatments for a wide variety of cancers, market stakeholders are continuing to adjust their daily practices around providing […]

Buy and Bill Trend: Are there Contradictions to Vendor or Pharma’s Reported Data

Buy and Bill Trend:  Are there Contradictions to Vendor or Pharma’s Reported Data Distribution based sales of specialty pharmaceuticals raises critical issues for manufacturers and providers as plan year 2016 decisions have been made and 2017 preparations begin by purchasers. For pharmaceutical manufacturers, the dilemma arises when (1) reimbursement is limited or eliminated under benefit […]